Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?
Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like STAAR Surgical (NASDAQ:STAA). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide STAAR Surgical with the means to add long-term value to shareholders.
See our latest analysis for STAAR Surgical
STAAR Surgical's Earnings Per Share Are Growing
The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. That makes EPS growth an attractive quality for any company. Recognition must be given to the that STAAR Surgical has grown EPS by 57% per year, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The music to the ears of STAAR Surgical shareholders is that EBIT margins have grown from 13% to 17% in the last 12 months and revenues are on an upwards trend as well. That's great to see, on both counts.
You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.
NasdaqGM:STAA Earnings and Revenue History September 27th 2022The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for STAAR Surgical's future EPS 100% free.
Are STAAR Surgical Insiders Aligned With All Shareholders?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. STAAR Surgical followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. To be specific, they have US$30m worth of shares. That shows significant buy-in, and may indicate conviction in the business strategy. Despite being just 0.9% of the company, the value of that investment is enough to show insiders have plenty riding on the venture.
It's good to see that insiders are invested in the company, but are remuneration levels reasonable? A brief analysis of the CEO compensation suggests they are. The median total compensation for CEOs of companies similar in size to STAAR Surgical, with market caps between US$2.0b and US$6.4b, is around US$6.9m.
The STAAR Surgical CEO received US$5.5m in compensation for the year ending December 2021. That comes in below the average for similar sized companies and seems pretty reasonable. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of a culture of integrity, in a broader sense.
Does STAAR Surgical Deserve A Spot On Your Watchlist?
STAAR Surgical's earnings have taken off in quite an impressive fashion. An added bonus for those interested is that management hold a heap of stock and the CEO pay is quite reasonable, illustrating good cash management. The strong EPS improvement suggests the businesses is humming along. Big growth can make big winners, so the writing on the wall tells us that STAAR Surgical is worth considering carefully. You still need to take note of risks, for example - STAAR Surgical has 1 warning sign we think you should be aware of.
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於初學者來説,收購一家向投資者講述一個好故事的公司似乎是一個好主意(也是一個令人興奮的前景),即使它目前沒有收入和利潤的記錄。有時,這些故事可能會矇蔽投資者的頭腦,導致他們以自己的情緒投資,而不是投資於良好的公司基本面。虧損的公司總是在爭分奪秒地實現財務可持續性,因此這些公司的投資者可能承擔了比他們應該承擔的更多的風險。
儘管處於科技股藍天投資的時代,許多投資者仍採取更傳統的策略;購買盈利的公司的股票,如STAAR外科(納斯達克:STAA)。即使這家公司得到了市場的公平估值,投資者也會同意,產生持續的利潤將繼續為STAAR Surgical提供為股東增加長期價值的手段。
查看我們對STAAR Surgical的最新分析
STAAR Surgical的每股收益正在增長
市場在短期內是一臺投票機,但從長期來看是一臺稱重機,所以你可以預期股價最終會跟隨每股收益(EPS)的結果。這使得每股收益的增長對任何公司來説都是一個有吸引力的品質。必須承認,在過去的三年中,STAAR Surgical的每股收益以每年57%的速度增長。儘管這種增長速度不會持續很長時間,但它肯定會吸引潛在投資者的目光。
要複核一家公司的增長,一種方法是觀察其收入和息税前利潤(EBIT)的變化情況。STAAR Surgical股東聽到的消息是,在過去12個月中,息税前利潤從13%增長到17%,收入也呈上升趨勢。無論從哪方面來看,這都是一件好事。
你可以在下面的圖表中看到該公司的收入和收益增長趨勢。點擊圖表查看確切的數字。
NasdaqGM:Staa收益和收入歷史2022年9月27日作為投資者,訣竅在於找到符合以下條件的公司要去在未來有好的表現,而不僅僅是在過去。雖然水晶球並不存在,但你可以查看我們對STAAR Surgical未來每股收益100%免費的共識分析師預測的可視化。
STAAR Surgical內部人士是否與所有股東一致?
公司領導人以股東的最佳利益行事是必要的,因此,內部投資總是對市場起到安撫作用。STAAR Surgical的追隨者將會感到安慰,因為他們知道內部人士擁有大量資本,這些資本將他們的最佳利益與更廣泛的股東羣體保持一致。具體地説,他們擁有價值3000萬美元的股票。這顯示出大量買入,並可能表明對商業戰略的信心。儘管只持有該公司0.9%的股份,但這筆投資的價值足以表明,內部人士對這家合資企業有很大的依賴。
看到內部人士投資公司是件好事,但薪酬水平合理嗎?對CEO薪酬的簡要分析表明,情況的確如此。市值在20億美元至64億美元之間的規模類似於STAAR Surgical的公司的首席執行官的總薪酬中值約為690萬美元。
這位STAAR Surgical首席執行官在截至2021年12月的一年中獲得了550萬美元的薪酬。這低於類似規模公司的平均水平,似乎相當合理。CEO薪酬水平不是投資者最重要的衡量標準,但當薪酬適中時,這確實有助於加強CEO與普通股東之間的一致性。在更廣泛的意義上,它也可以是一種誠信文化的標誌。
STAAR Surgical值得在你的觀察名單上佔有一席之地嗎?
STAAR Surgical的收入以相當令人印象深刻的方式增長。對於那些感興趣的人來説,一個額外的好處是,管理層持有大量股票,首席執行官的薪酬相當合理,這表明了良好的現金管理。每股收益的強勁改善表明,企業進展順利。大增長可以成為大贏家,所以不祥之兆告訴我們,STAAR Surgical值得仔細考慮。例如,你仍然需要注意風險-STAAR Surgical有1個警告標誌我們認為你應該意識到。
總是有可能做得很好,購買股票不是不斷增長的收入和不要有內部人士購買股票。但對於那些考慮這些重要指標的人,我們建議您查看以下公司做擁有這些功能。你可以在這裏訪問它們的免費列表。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧